DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances Manufacturers
- Sub-Industry: N/A
- Symbol: NASDAQ:DBVT
- CUSIP: N/A
- Web: www.dbv-technologies.com
- Market Cap: $2.16092 billion
- Outstanding Shares: 46,000,000
- 50 Day Moving Avg: $36.08
- 200 Day Moving Avg: $35.06
- 52 Week Range: $31.87 - $44.95
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.06
- P/E Growth: 0.00
- Annual Revenue: $8.6 million
- Price / Sales: 234.28
- Book Value: $5.63 per share
- Price / Book: 7.78
- EBIDTA: ($130,950,000.00)
- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 9.39%
- Quick Ratio: 9.39%
- Average Volume: 116,610 shs.
- Beta: 1.44
- Short Ratio: 4.73
Frequently Asked Questions for DBV Technologies S.A. (NASDAQ:DBVT)
What is DBV Technologies S.A.'s stock symbol?
DBV Technologies S.A. trades on the NASDAQ under the ticker symbol "DBVT."
How were DBV Technologies S.A.'s earnings last quarter?
DBV Technologies S.A. (NASDAQ:DBVT) released its earnings results on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.35. View DBV Technologies S.A.'s Earnings History.
Where is DBV Technologies S.A.'s stock going? Where will DBV Technologies S.A.'s stock price be in 2017?
8 analysts have issued twelve-month price objectives for DBV Technologies S.A.'s shares. Their predictions range from $46.00 to $54.00. On average, they expect DBV Technologies S.A.'s share price to reach $48.80 in the next twelve months. View Analyst Ratings for DBV Technologies S.A..
Who are some of DBV Technologies S.A.'s key competitors?
Some companies that are related to DBV Technologies S.A. include bluebird bio (BLUE), Akorn (AKRX), Galapagos NV (GLPG), Integra LifeSciences Holdings Corporation (IART), Neurocrine Biosciences (NBIX), Patterson Companies (PDCO), HealthSouth Corporation (HLS), Molina Healthcare (MOH), NuVasive (NUVA), Clovis Oncology (CLVS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Opko Health (OPK), Nektar Therapeutics (NKTR), ICU Medical (ICUI), Chemed Corp. (CHE), Intercept Pharmaceuticals (ICPT) and Cantel Medical Corp. (CMD).
Who are DBV Technologies S.A.'s key executives?
DBV Technologies S.A.'s management team includes the folowing people:
- Pierre-Henri Benhamou, Chairman of the Board, Chief Executive Officer
- David Schilansky, Chief Operating Officer
- Hugh A. Sampson M.D., Chief Scientific Officer
- Lucie Mondoulet, Director of Research
- Nathalie Donne, Director of Corporate Communication & Business Development
- Veronique Foutel, Director of Strategic Marketing
- Wence Agbotounou, Chief Clinical Trial Officer
- Bertrand Dupont, Industrial Director
- Pascale Ehouarn, Industrial Development and Production Director
- Laurent Martin, Director of Regulatory Affairs
Who owns DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include Exane Asset Management (0.31%), GW&K Investment Management LLC (0.22%) and Sit Investment Associates Inc. (0.04%). View Institutional Ownership Trends for DBV Technologies S.A..
Who sold DBV Technologies S.A. stock? Who is selling DBV Technologies S.A. stock?
Who bought DBV Technologies S.A. stock? Who is buying DBV Technologies S.A. stock?
How do I buy DBV Technologies S.A. stock?
Shares of DBV Technologies S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DBV Technologies S.A.'s stock price today?
MarketBeat Community Rating for DBV Technologies S.A. (NASDAQ DBVT)MarketBeat's community ratings are surveys of what our community members think about DBV Technologies S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of DBV Technologies S.A. stock can currently be purchased for approximately $43.80.
Earnings History for DBV Technologies S.A. (NASDAQ:DBVT)Earnings History by Quarter for DBV Technologies S.A. (NASDAQ DBVT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for DBV Technologies S.A. (NASDAQ:DBVT)
2017 EPS Consensus Estimate: ($4.00)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for DBV Technologies S.A. (NASDAQ:DBVT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for DBV Technologies S.A. (NASDAQ:DBVT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for DBV Technologies S.A. (NASDAQ:DBVT)
Latest Headlines for DBV Technologies S.A. (NASDAQ:DBVT)
DBV Technologies S.A. (DBVT) Chart for Sunday, July, 23, 2017